Market
What will be Novo Nordisk's next strategic move post-CagriSema trial results by June 2025?
2
Resolution / Starting Odds
Focus on improving CagriSema • 25%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%
Official announcements and press releases from Novo Nordisk
Story
Novo Nordisk Shares Plunge 29% After CagriSema Falls Short of 25% Weight Loss Target
Dec 20, 2024, 12:30 PM
Novo Nordisk announced that its experimental obesity drug CagriSema achieved a 22.7% weight loss in adults with obesity or overweight in the REDEFINE 1 Phase 3 trial after 68 weeks. While this result demonstrated superior weight loss compared to semaglutide 2.4 mg (16.1%), cagrilintide 2.4 mg (11.8%), and placebo (2.3%), it fell short of the company's anticipated target of 25% weight loss. Following the announcement, Novo Nordisk's shares plunged as much as 29%, marking the largest single-day drop on record for the company and erasing over $140 billion in market value.
View original story
Similar markets
No • 50%
Yes • 50%
Seek further trials • 25%
Partner with another company • 25%
Discontinue development • 25%
Submit for regulatory approval • 25%
No • 50%
Yes • 50%
Other regulatory actions • 25%
Safety label update • 25%
No action taken • 25%
Product recall • 25%
Weight loss between 17.5% and 19% • 25%
Weight loss > 20.7% • 25%
Weight loss between 19% and 20.7% • 25%
Weight loss < 17.5% • 25%
Meets expectations • 25%
Exceeds expectations • 25%
Trial cancelled • 25%
Falls short of expectations • 25%
No • 50%
Yes • 50%
Heart disease • 25%
Stroke • 25%
Kidney disease • 25%
Brain disorders • 25%
No major announcement • 25%
Improved results for CagriSema • 25%
New drug entering Phase 3 trials • 25%
Partnership with another company • 25%
Slightly increase • 25%
Decrease • 25%
Significantly increase • 25%
No change • 25%